Drug Coated Balloon Angioplasty in Peripheral Vasculature: Review of Literature | Zendy

Valerie F. Civelli | Zendy; Vincent Ngo | Zendy; Mukul Anand | Zendy; Ojas Sharma | Zendy; Sarabjeet Singh | Zendy; Sanjiv Sharma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Drug Coated Balloon Angioplasty in Peripheral Vasculature: Review of Literature

Author(s) -

Valerie F. Civelli,

Vincent Ngo,

Mukul Anand,

Ojas Sharma,

Sarabjeet Singh,

Sanjiv Sharma

Publication year - 2019

Publication title -

clinical cardiology and cardiovascular interventions

Language(s) - English

Resource type - Journals

ISSN - 2641-0419

DOI - 10.31579/2641-0419/034

Subject(s) - angioplasty , restenosis , medicine , arterial disease , balloon , paclitaxel , atherectomy , peripheral , surgery , vascular disease , stent , radiology , chemotherapy

Drug-coated balloons (DCB) are commonly used to treat peripheral artery disease (PAD) and are often used in combination with or in place of a stent or rotational atherectomy. DCB’s are manufactured with the drug, Paclitaxel with the first-line indication of preventing restenosis of arteries following an intervention. Recent literature has suggested an increased mortality risk at years 2 and 5 post DCB angioplasty. Inspired by Katsanos et al. and their important work in researching outcomes for DCBs in PAD, we conducted a thorough review of all literature to compile an informed conclusion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research